A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

March 27, 2024

Study Completion Date

March 27, 2024

Conditions
COVID-19
Interventions
DRUG

Tocilizumab

Participants will receive intravenous (IV) tocilizumab

Trial Locations (25)

10000

Klinika Za Djecje Bolesti Zagreb, Zagreb

"University Hospital for Infection Diseases Dr. Fran Mihaljevic - PPDS", Zagreb

11030

Feinstein Institute for Medical Research, Manhasset

23900

ASST di Lecco - Presidio Ospedaliero A. Manzoni di Lecco, Lecco

28009

Hospital Infantil Universitario Niño Jesus; Sección de Neuropediatria, Madrid

28041

Hospital Universitario 12 De Octubre, Madrid

28046

Hospital Universitario La Paz - PPDS, Madrid

34295

CHRU Montpellier; SMPEA Peyre Plantade Centre de Ressources Autisme, Montpellier

50937

Uniklinik Köln, Cologne

60637

The University of Chicago, Chicago

75015

Hospital Necker, Paris

89081

Universitätsklinikum Ulm, Ulm

90095

Reagan UCLA Medical Center, Los Angeles

94275

Assistance Publique Hopitaux de Paris, Val-de-Marne

48858-3803

Central Michigan University College of Medicine, Mount Pleasant

44106-2624

University Hospitals Cleveland Medical Center, Rainbow Babies and Childrens Hospital, Cleveland

77030-3005

UT Physicians - Pediatric Center - Texas Medical Center, Houston

84108-1287

University of Utah - PPDS, Salt Lake City

90020-090

Santa Casa de Misericordia de Porto Alegre, Porto Alegre

546 42

Hippokration Hospital, Thessaloniki

00165

IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN, Rome

60-572

Szpital Kliniczny im Karola Jonschera Uniwersytetu Medycznego im Karola Marcinkowskiego w Poznaniu, Poznan

0001

Global Clinical Trials Sunnyside, Pretoria

08950

Hospital Sant Joan de Deu - PIN; Unitat de Recerca - Farmacia, Esplugues de Llobregat

NE1 4LP

Great North Childrens Hospital, Newcastle upon Tyne

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY